Arbor Biotechnologies is developing genetic medicines to treat genetic diseases.To treat a genetic disease, the underlying genetic pathology must first be understood. With this knowledge, Arbor can use their toolbox of CRISPR-based genomic editors to tailor an approach to the disease. Arbor uses their discovery engine to uncover useful genomic editors. This involves high-throughput testing of protein systems to identify hits and then AI and machine learning to improve and streamline future screening cycles. Arbor has already created and published DNA nucleases, RNA nucleases and transposases that can now be used in therapeutics. Arbor’s initial focus is on genetic liver diseases.